Furthermore, many PARP1 inhibitors were demonstrated to be not only effective against familial DNA repair defective carcinomas, but also against HR-proficient cancers, like HR-proficient HER2+ breast carcinoma and Ewing’s sarcoma, in pre-clinical or clinical studies [14,15,16]. This evidence concerns the gene PARP1 and carcinoma.